NCT02508467 2024-04-12A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular CarcinomaBlueprint Medicines CorporationPhase 1 Completed146 enrolled
NCT04194801 2023-02-06A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular CarcinomaCStone PharmaceuticalsPhase 1/2 Completed26 enrolled 31 charts